NKGen Biotech, Inc.

Graf Acquisition Corp. IV, trading on Nasdaq under ticker GFOR, is a blank-check company sponsored by Graf Acquisition Management, LLC and completed its initial public offering in 2021 with a focus on the healthcare and life sciences sector. The SPAC pursued a business combination with NKGen Biotech, Inc., a clinical-stage biotherapeutics company developing natural killer cell-based therapies targeting oncology and neurodegenerative indications. NKGen Biotech filed a 10-Q with the SEC on August 14, 2023, under accession number 0001410578-23-001926, reflecting the combined company's financial disclosures in the period surrounding the de-SPAC transaction. Sign up at SpacDesk for full filing histories, sponsor profiles, and deal analytics across the entire SPAC universe.